NCT04417088 2026-03-20
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
Phase 1/2 Completed
Clinical Trials
9 trialsNCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT04440358 2026-01-20
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
InSightec
Phase 1/2 Completed
NCT05902169 2025-11-10
SONOBIRD
CarThera
Phase 3 Active not recruiting
NCT02684058 2023-12-13
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Phase 2 Completed
NCT03744026 2022-09-07
SC9-GBM-01
CarThera
Phase 1/2 Completed
NCT01934361 2020-12-09
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Novartis
Phase 1 Completed
NCT00650949 2013-05-03
Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma
Gilead Sciences
Phase 1/2 Terminated
NCT00635557 2011-03-25
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
Myrexis Inc.
Phase 1/2 Unknown